Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single ascending dose study of intravenous T20K in healthy male volunteers
NL-OMON48273Phase 1Active, not recruiting
- Sponsor
- Cyxone
- Start
- Jul 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing T20K with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jul 2019; status: active, not recruiting.
02
Drugs
T20K
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON48273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48273.